FDA Spells Out Biosimilar Supplement Filing Rules
Published Date: 9/9/2025
Notice
Summary
The FDA just released final guidance to help companies classify and submit supplements for biosimilar drugs under new rules from BsUFA III. This update affects anyone making changes to approved biosimilar products and sets clear deadlines for reviews, helping speed up the process. The new rules started in 2023 and aim to make reviews smoother without extra fees.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in